Emery Pharma Receives Cal/OSHA Golden Gate Recognition for Its Commitment to Safety
Good Research Is Done Safely – for Employees, Clients, and the Environment ALAMEDA, Calif. – October 2026 – At Emery Pharma, we believe that good research is done safely. Protecting…
FDA Recent Updates to the Recommended Interim Acceptable Intake (AI) Limits for Certain Nitrosamine Impurities of Approved or Currently Marketed Products
Alameda, CA-The U.S. Food and Drug Administration (FDA) has reassessed the recommended Acceptable Intake (AI) limit for 8 out of 9 listed products in the CDER Nitrosamine Impurity Acceptable Intake…
Come see us at WRIB 2026
Alameda, CA – Emery Pharma will be exhibiting at the Workshops on Recent Issues in Bioanalysis (WRIB) conference, held on April 14–16, 2026 in Dallas, Texas. This year, Emery Pharma will…
FDA Expands Regulatory Flexibility for Cell and Gene Therapies Accelerating Innovation While Preserving Quality
Alameda, CA-The U.S. Food and Drug Administration (FDA) has announced increased regulatory flexibility for cell and gene therapies (CGTs), signaling a major step forward in advancing innovative medicines for patients…
Albrem Biopharma and Emery Pharma Announce Strategic Partnership to Advance Protein Target Development
Albrem Biopharma, a pioneering biotech company specializing in cell-free protein synthesis and protein development, and Emery Pharma, a leading contract research organization focused on analytical chemistry and bioanalysis, are pleased…
Emery Pharma Co-Sponsors PDA West Coast Event on CMC Strategy for Parenteral and Novel Drug Modalities
Emery Pharma announced its role as co-sponsor and host of the Parenteral Drug Association (PDA) – West Coast Chapter upcoming industry program focused on CMC considerations for parenteral drug products…
Emery Pharma and Fortrea Launch Podcast on Restoring Rifampin for Safer DDI Studies
Alameda, CA | July 28, 2025 – Emery Pharma, a leading GLP/GMP-certified analytical laboratory, is proud to announce the release of a special podcast episode featuring Dr. Marcus Stavchansky, Global…
Nitrosamine Risk Assessment: Are You Prepared for the August 1, 2025 Deadline?
The FDA’s deadline is fast approaching. Let us help you stay compliant. Whether you’re a formulation scientist, process chemist, analytical chemist, regulatory affairs specialist, or drug delivery expert, understanding nitrosamines—and…
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies Source: GlobeNewswire DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the…
Emery Pharma and Rayner Announce Publication of a Successful Validation of Bioanalytical Method for Quantifying Ketorolac in Human Vitreous and Aqueous Humor Using a Surrogate Matrix of Human Plasma, in Accordance with ICH M10 Guidelines
Emery Pharma, a leading contract research organization specializing in bioanalytical method development and validation, has partnered with Rayner to develop and validate a novel bioanalytical method for measuring ketorolac concentrations…